Ask AI
ProCE Banner Activity

LIBRETTO-432: Phase III Trial of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion–Positive NSCLC

Conference Coverage
Slideset

Results from the phase III LIBRETTO-432 trial showed clinically meaningful and statistically significant event-free survival benefits with selpercatinib vs placebo in patients with stage IB-IIIA RET fusion–positive NSCLC.

Released: June 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Incyte Corporation.

Incyte Corporation

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of lung cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate pivotal ASCO 2026 lung cancer data and expert guidance to optimize biomarker-driven treatment selection, sequencing, and monitoring across disease stages

  • Apply prognostic and predictive biomarkers to accurately identify patients most likely to benefit from targeted, immunotherapy-based, and emerging treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for lung cancer to accelerate their effective incorporation into clinical practice